Compare Sana Biotechnology Inc (SANA) vs TORM plc (TRMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs TORM plc — how do they compare? Sana Biotechnology Inc trades at $3.24 (market cap $1.03B), while TORM plc trades at $33.34 (market cap $3.58B). The key difference: TORM plc is far larger — about 3.5× Sana Biotechnology Inc's market cap, and TORM plc pays a 12.65% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| SANA | TRMD | |
|---|---|---|
Market Cap | $1.03B | $3.58B |
Sector | Health | Technology |
52-Week High | $5.92 | $35.46 |
52-Week Low | $2.68 | $19.39 |
Enterprise Value | $946.04M | $4.28B |
Dividend Yield | — | 12.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.45, down 10.39% in the past 24 hours, reflecting bearish technical signals and negative profitability. The company reported a net loss of $244.17 million for 2025, with a price-to-book ratio of 6.68. Recent news includes investor conference presentations and a peer-reviewed publication in The New England Journal of Medicine highlighting clinical data.
Despite analyst consensus favoring a 'Buy' rating (81.82% of 11 analysts), the stock faces significant risks from negative cash flows, high losses, and potential fiduciary concerns. Upside hinges on successful clinical developments and improved financial performance, but current fundamentals suggest caution for investors.
TRMD trades at $34.94, down 0.68% today, with a bullish technical signal from moving averages and strong support at $34. The company reported record Q2 2026 earnings with $3.25 EPS, though slightly missing estimates, and maintains robust profitability with a 35.52% net margin. Recent news highlights a capital increase from RSU exercises and a strong dividend of $2.40 payable in September 2026.
Outlook is positive with 100% analyst buy ratings, underpinned by strong cash flow growth and high ROE of 26.84%. Risks include reliance on volatile freight rates and potential market corrections given elevated RSI levels. The stock presents value with a low P/E of 5.75, but investors should monitor earnings consistency and global trade dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About TORM plc
TORM plc is one of the world's largest owners and operators of product tankers, specializing in the transportation of refined oil products like gasoline, jet fuel, and diesel. Operating under its integrated 'One TORM' model, the company maintains a modern, wholly-owned fleet of nearly 90 vessels. It is widely recognized by investors for its aggressive variable dividend policy, which returns a significant portion of its cash flow directly to shareholders during periods of high freight rates.
Read more on TRMD →
